Kluwer Patent Blog

Mundipharma v. Cimex et al., District Court The Hague (Rechtbank Den Haag), 30 September 2009

Klaas de Vries · Wednesday, September 30th, 2009

The District Court of The Hague finds that the generic products of the defendants fall under the scope of protection of both of Mundipharma's patents, which are related to controlled release oxycodone formulations. According to the District Court, the scope of protection of the patents is not limited to products wherein all oxycodone is within the coating which controls its release. Furthermore, the term 'spheronising agent' is not deemed to be limited to agents that have assisted in forming spheroids but also comprises materials that assist in maintaining the spherical shape of a starting compound.

A full summary of this case has been published on Kluwer IP Law.

To make sure you do not miss out on regular updates from the Kluwer Patent Blog, please subscribe here.

Kluwer IP Law


The **2022 Future Ready Lawyer survey** showed that 79% of lawyers think that the importance of legal technology will increase for next year. With Kluwer IP Law you can navigate the increasingly global practice of IP law with specialized, local and cross-border information and tools from every preferred location. Are you, as an IP professional, ready for the future?

Learn how **Kluwer IP Law** can support you.

79% of the lawyers think that the importance of legal technology will increase for next year.

Drive change with Kluwer IP Law.

The master resource for Intellectual Property rights and registration.



2022 SURVEY REPORT
The Wolters Kluwer Future Ready Lawyer

Leading change



This entry was posted on Wednesday, September 30th, 2009 at 6:24 am and is filed under (Indirect) infringement, Case Law, Extent of Protection, Netherlands, Scope of protection, Validity You can follow any responses to this entry through the Comments (RSS) feed. Both comments and pings are currently closed.